公开(公告)号：US20120322819A1

公开(公告)日：2012-12-20

申请号：US13580056

申请日：2011-02-25

Applicant: Toru Miura ,  Kazuhiro Onogi ,  Junya Tagashira ,  Gen Watanabe ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

Inventor： Toru Miura ,  Kazuhiro Onogi ,  Junya Tagashira ,  Gen Watanabe ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

IPC: A61K31/506 ,  C07D413/14 ,  A61P9/00 ,  A61P3/04 ,  A61P9/10 ,  A61P3/00 ,  A61P3/10 ,  C07D413/10 ,  A61P9/12

CPC classification number: C07D413/10 ,  C07D413/14

Abstract: Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPARγ activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R1 and R2 represent a C1-6 alkyl group, R3 represents a C1-6 alkyl group which may contain one or more substituent groups selected from group A, or a C3-8 cycloalkyl group which may contain one or more substituent groups selected from group B.) which represents the compound, and salts thereof, solvates thereof, and medicinal compositions containing any of these.

Abstract translation: 公开了含有血管紧张素II受体阻断和PPARγ活化作用的新型化合物和药物制剂，用作预防和/或治疗高血压，心脏病，心绞痛，脑血管障碍，脑循环障碍， 缺血性外周循环损伤，肾脏疾病，动脉硬化，炎性疾病，2型糖尿病，糖尿病并发症，胰岛素抵抗综合征，X综合征，代谢综合征和高胰岛素血症。 进一步公开的是通式I（其中R 1和R 2中的一个或两个表示C 1-6烷基，R 3表示可以含有一个或多个选自A组的取代基的C 1-6烷基或C 3-8 可以含有一个或多个选自B组的取代基的环烷基），其代表该化合物及其盐，其溶剂合物，以及含有这些中的任何一种的药物组合物。

公开(公告)号：US20120259015A1

公开(公告)日：2012-10-11

申请号：US13524134

申请日：2012-06-15

Applicant: Yuji YOSHIKAWA ,  Megumi YAMAMOTO ,  Naoto ISHIBASHI ,  Mami SEKI

Inventor： Yuji YOSHIKAWA ,  Megumi YAMAMOTO ,  Naoto ISHIBASHI ,  Mami SEKI

IPC: A61K31/202 ,  A61P1/16

CPC classification number: A61K31/201

Abstract: A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.

Abstract translation: 一种用于预防和/或治疗肝脂肪变性或非酒精性脂肪性肝炎的药物，其包含聚异戊二烯基化合物（例如3,7,11,15-四甲基-2,4,6,10,14-十六碳五烯酸）作为 活性成分。

公开(公告)号：US08273766B2

公开(公告)日：2012-09-25

申请号：US12531318

申请日：2008-04-03

Applicant: Seiichi Sato ,  Junya Tagashira ,  Shunji Takemura ,  Yoshiharu Miyake ,  Tetsuya Ishikawa ,  Toshiharu Arai ,  Takahiro Ito ,  Takuya Hara

Inventor： Seiichi Sato ,  Junya Tagashira ,  Shunji Takemura ,  Yoshiharu Miyake ,  Tetsuya Ishikawa ,  Toshiharu Arai ,  Takahiro Ito ,  Takuya Hara

IPC: C07D217/18 ,  A61K31/47

CPC classification number: C07D217/04 ,  A61K31/472 ,  A61K31/4725 ,  C07D217/02 ,  C07D217/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12

Abstract: The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

Abstract translation: 本发明涉及可用作3型趋化因子受体（CCR3）拮抗剂的特定四氢异喹啉化合物，以及包含其作为活性成分的药物组合物。 本发明的四氢异喹啉化合物可用于治疗或预防CCR3参与的疾病。

公开(公告)号：US08267996B2

公开(公告)日：2012-09-18

申请号：US11912499

申请日：2005-05-20

Applicant: Kazuharu Niwa ,  Yutaka Kumazawa ,  Atsushi Kobayashi

Inventor： Kazuharu Niwa ,  Yutaka Kumazawa ,  Atsushi Kobayashi

IPC: A61F2/16

CPC classification number: A61F2/1613 ,  A61F2002/1683

Abstract: An intraocularlens of novel structure by which the outer circumferential part of an optical portion can be pressed stably against a posterior capsule under worn state and crisis of secondary cataract can be suppressed more advantageously. A pair of coupling portions (14, 14) are formed to hold an optical portion (12) between them in one direction perpendicular to the optical axis, wherein the outer fringe parts of the coupling portions (14, 14) are made thicker than the outer fringe part of the optical portion (12), a pair of supporting portions (16, 16) are formed to project from the outer fringe parts of the coupling portions (14, 14) and a edge contour part (32) is formed continuously on the outer fringe parts of the optical portion (12) and respective posterior surfaces (20, 24) of the coupling portions (14, 14) so as to extend smoothly along the entire circumference thereof.

Abstract translation: 新型结构的眼内透镜可以更有利地抑制光学部分的外圆周部分在佩戴状态下被稳定地压靠在后囊上，并且可以更有利地抑制二次白内障的危机。 形成一对联接部分（14,14），以在垂直于光轴的一个方向上在其间保持光学部分（12），其中联接部分（14,14）的外边缘部分比 光学部分（12）的外边缘部分，一对支撑部分（16,16）形成为从连接部分（14,14）的外边缘部分突出，并且连续地形成边缘轮廓部分（32） 在所述光学部分（12）的外边缘部分和所述联接部分（14,14）的各个后表面（20,24）之间沿着其整个圆周平滑地延伸。

公开(公告)号：US20120224144A1

公开(公告)日：2012-09-06

申请号：US13351352

申请日：2012-01-17

Applicant: Shigeru TAKIMOTO ,  Satoshi SHIMADA ,  Masayoshi OOUCHI

Inventor： Shigeru TAKIMOTO ,  Satoshi SHIMADA ,  Masayoshi OOUCHI

IPC: A61B3/024

CPC classification number: A61B3/024

Abstract: In a perimeter having means for measuring a visual field of an eye to be examined, means for monitoring fixation state and means for lighting the eye to be examined with a brightness necessary for monitoring the fixation state of the eye to be examined and means for correcting visibility, means for correcting visibility is provided so as to be freely moved between a set position corresponding to a measurement position of the eye to be examined and a stored position retracted to an outer periphery of a projection member. Such a perimeter further has means for detecting whether means for correcting visibility is at the set position or the stored position and an illustration controller for changing brightness of the illumination onto the eye to be examined through the means for lighting according to the detected position of means for correcting visibility.

Abstract translation: 在具有用于测量要检查的眼睛的视场的装置的周边上，用于监视固定状态的装置和用于监视所要检查的眼睛的固定状态所必需的亮度来点亮待检眼的装置，以及用于校正的装置 提供可见度，用于校正可见度的装置，以便在与待检查的眼睛的测量位置相对应的设置位置与缩回到突出部件的外周的存储位置之间自由移动。 这样的周边还具有用于检测用于校正可见度的装置是否处于设定位置或存储位置的装置，以及用于根据检测到的装置位置，通过照明装置将照明亮度改变为要检查的眼睛的亮度的插图控制器 用于校正可见性。

公开(公告)号：US08236180B2

公开(公告)日：2012-08-07

申请号：US12600215

申请日：2008-05-21

Applicant: Katsumi Yabusaki

Inventor： Katsumi Yabusaki

IPC: C02F1/28

CPC classification number: C07C235/06 ,  B01J20/22 ,  C02F1/001 ,  C02F1/285 ,  C02F1/66 ,  C02F2101/108 ,  C02F2103/16 ,  C02F2209/06 ,  C02F2305/04 ,  C07C235/10 ,  C07C305/04 ,  Y10S210/902

Abstract: Disclosed is a boron adsorbent having an excellent adsorbing ability against boron contained in a solution, which is inexpensive and has high general versatility. Also disclosed is a boron removal method which can remove boron efficiently in a simple manner. An amide derivative represented by the general formula (1) is added to a boron-containing water under alkaline conditions to cause the adsorption of boron to the amide derivative. Then, a cation source having two or more valencies is added to the water to cause the aggregation of the amide body. The aggregated amide body is removed from the water. In the general formula (1), m represents 1 or 2; X represents —CH2OH, —CHO or —COOH; n represents an integer of 2 to 5; X are independent from each other and n are independent from each other when m represents 2; and Y represents a monovalent hydrocarbon group having 6 to 16 carbon atoms when m is 1, and represents a divalent hydrocarbon group having 8 to 18 carbon atoms when m is 2.

Abstract translation: 公开了一种对于溶液中含有的硼的吸附能力优异的硼吸附剂，其成本低廉且通用性高。 还公开了能够以简单的方式有效去除硼的硼去除方法。 在碱性条件下，将通式（1）表示的酰胺衍生物加入到含硼水中，使硼吸附到酰胺衍生物上。 然后，将具有两个或更多个价态的阳离子源加入到水中以引起酰胺体的聚集。 聚集的酰胺体从水中除去。 在通式（1）中，m表示1或2; X表示-CH 2 OH，-CHO或-COOH; n表示2〜5的整数， X彼此独立，当m表示2时，n彼此独立; 而当m为1时，Y表示碳原子数为6〜16的一价烃基，m为2时，表示碳原子数为8〜18的二价烃基。

公开(公告)号：US20120165353A1

公开(公告)日：2012-06-28

申请号：US13394266

申请日：2010-09-29

Applicant: Toru Miura ,  Seiichi Sato ,  Hajime Yamada ,  Junya Tagashira ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

Inventor： Toru Miura ,  Seiichi Sato ,  Hajime Yamada ,  Junya Tagashira ,  Ryohei Sekimoto ,  Rie Ishida ,  Hitomi Aoki ,  Tadaaki Ohgiya

IPC: A61K31/506 ,  C07D413/14 ,  A61P9/00 ,  A61P13/12 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  C07D401/14 ,  A61P3/00

CPC classification number: C07D401/14 ,  A61K31/422 ,  A61K31/4427 ,  C07D413/14

Abstract: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

Abstract translation: 公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物，因此可用作高血压，心脏病，动脉硬化，2型糖尿病，糖尿病并发症的预防和/或治疗剂 ，代谢综合征等; 和含有该化合物的药物组合物。 具体公开的是：由通式（I）表示的化合物（其中环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮 原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3，R4，R5分别表示氢原子，卤素原子，C1-6烷基， 卤代C 1-6烷基或可具有取代基的C 1-6烷氧基），化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物，该盐或溶剂化物的药物组合物。

公开(公告)号：US20120108581A1

公开(公告)日：2012-05-03

申请号：US13260711

申请日：2010-03-25

Applicant: Masanori Ashikawa ,  Toshiharu Morimoto ,  Hajime Yamada ,  Shunji Takemura ,  Tatsuaki Nishiyama ,  Takeshi Doi ,  Hiroyuki Ishiwata

Inventor： Masanori Ashikawa ,  Toshiharu Morimoto ,  Hajime Yamada ,  Shunji Takemura ,  Tatsuaki Nishiyama ,  Takeshi Doi ,  Hiroyuki Ishiwata

IPC: A61K31/473 ,  A61K31/4375 ,  C12N5/02 ,  C07D495/04 ,  A61K31/4365 ,  A61P7/06 ,  A61K31/4745 ,  C07D491/052 ,  A61K31/4741 ,  C07D491/056 ,  C07D498/04 ,  A61K31/5383 ,  C07D471/04 ,  C07D221/10

CPC classification number: C07D221/06 ,  C07D471/04 ,  C07D491/052 ,  C07D491/056 ,  C07D498/04

Abstract: The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R7, a sulfur atom or an oxygen atom, R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, C1-6 alkyl group or C3-6 cycloalkyl group, and R4, R5 and R6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

Abstract translation: 本发明提供具有EPO生产促进作用和/或血红蛋白生产促进作用的低分子量化合物。 本发明涉及由以下通式（1）表示的稠合哌啶化合物：其中环A表示C10-14芳基或5-至10-元杂环基，X表示N-R7，硫原子 或氧原子，R 1，R 2，R 2'，R 3和R 3'独立地表示氢原子，C 1-6烷基或C 3-6环烷基，R 4，R 5和R 6独立地表示氢原子或卤素原子） 或其盐，或其溶剂合物。

公开(公告)号：US08113656B2

公开(公告)日：2012-02-14

申请号：US12804131

申请日：2010-07-14

Applicant: Takayoshi Suzuki

Inventor： Takayoshi Suzuki

IPC: A61B3/14 ,  A61B3/10

CPC classification number: A61B3/12 ,  A61B3/14 ,  G03B35/08

Abstract: A monocular image of a fundus of an eye under examination is captured via a photographic stop for monocular photography, and two stereographically viewed images are captured with a parallax via two photographic stops for stereographic photography that are decentered from a photographic optical axis. Defocused images are captured in the stereographic photography due to the deviation of the photographic stops from the optical axis. A corrective lens is inserted into the photographic optical path in order to correct the defocus in the stereographic photography. This makes it possible to readily correct defocus generated by deviation of the photographic stops from the photographic optical axis even when switching between monocular and stereographic photography modes.

Abstract translation: 通过用于单目摄影的照片停止拍摄被检眼的眼底的单眼图像，并且通过用于从摄影光轴偏心的立体摄影的两个照相停止点，通过视差捕获两个立体观看图像。 由于摄影停止与光轴的偏离，在立体摄影中捕获散焦图像。 为了校正立体摄影中的散焦，将矫正透镜插入摄影光路中。 这使得即使在单目和立体摄影模式之间切换时，也可以容易地校正由拍摄停止物从摄影光轴偏离产生的散焦。

公开(公告)号：US08106053B2

公开(公告)日：2012-01-31

申请号：US12665492

申请日：2008-06-19

Applicant: Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

Inventor： Noriaki Gomi ,  Shinji Ina ,  Kenjirou Yamana ,  Yoshio Kaneko

IPC: A61K31/50 ,  A61K31/501 ,  C07D237/02

CPC classification number: C07D237/14 ,  C07D401/06 ,  C07D405/12 ,  C07D417/06

Abstract: To find a compound having a tissue fibrinosis-inhibitory activity and a fibrinolytic activity, and to provide a novel compound that is useful for preventing and/or treating tissue fibrinosis diseases (pulmonary fibrosis, renal fibrosis etc.), diseases caused by pathological blood clots such as ischemic heart diseases (myocardial infarction, angina), intraatrial thrombus, pulmonary embolism, deep venous thrombosis, disseminated intravascular coagulation, ischemic cerebral diseases (cerebral infarction, cerebral bleeding) and arteriosclerosis and the like. To provide a pharmaceutical drug comprising a 5-phenyl-3-pyridazinone derivative represented by the following general formula (I): and an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, useful for preventing and/or treating disease conditions or symptoms mediated by plasminogen activator inhibitor-1.

Abstract translation: 为了找到具有组织纤维蛋白沉积抑制活性和纤维蛋白溶解活性的化合物，并提供可用于预防和/或治疗组织纤维蛋白病（肺纤维化，肾纤维化等）的新型化合物，由病理性血块引起的疾病 心肌梗塞，心绞痛，心内膜血栓，肺栓塞，深静脉血栓形成，弥散性血管内凝血，缺血性脑疾病（脑梗死，脑出血），动脉硬化等。 提供一种药物，其含有下述通式（I）表示的5-苯基-3-哒嗪酮衍生物及其旋光异构体或其药学上可接受的盐或其水合物或溶剂合物，其用于预防和/ 或治疗由纤溶酶原激活物抑制剂-1介导的疾病状况或症状。